INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 175 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2014. The put-call ratio across all filers is 1.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $315,000 | -67.2% | 23,135 | -62.4% | 0.00% | – |
| Q3 2021 | $959,000 | -34.4% | 61,455 | -10.0% | 0.00% | -100.0% |
| Q2 2021 | $1,461,000 | +744.5% | 68,317 | +818.6% | 0.00% | – |
| Q1 2021 | $173,000 | -46.6% | 7,437 | -28.1% | 0.00% | – |
| Q4 2020 | $324,000 | -53.5% | 10,337 | -40.0% | 0.00% | -100.0% |
| Q3 2020 | $697,000 | +15.2% | 17,236 | +24.8% | 0.00% | 0.0% |
| Q2 2020 | $605,000 | -40.9% | 13,807 | -18.8% | 0.00% | 0.0% |
| Q1 2020 | $1,024,000 | -34.5% | 17,010 | +34.8% | 0.00% | 0.0% |
| Q4 2019 | $1,563,000 | +33.0% | 12,616 | -28.7% | 0.00% | 0.0% |
| Q3 2019 | $1,175,000 | -13.5% | 17,698 | +3.7% | 0.00% | 0.0% |
| Q2 2019 | $1,358,000 | -16.9% | 17,060 | +16.7% | 0.00% | 0.0% |
| Q1 2019 | $1,635,000 | +13.9% | 14,613 | +2.6% | 0.00% | 0.0% |
| Q4 2018 | $1,435,000 | -8.1% | 14,240 | +15.2% | 0.00% | 0.0% |
| Q3 2018 | $1,562,000 | +69.6% | 12,363 | +12.6% | 0.00% | 0.0% |
| Q2 2018 | $921,000 | -8.5% | 10,978 | -32.9% | 0.00% | 0.0% |
| Q1 2018 | $1,007,000 | -9.7% | 16,363 | -14.2% | 0.00% | 0.0% |
| Q4 2017 | $1,115,000 | +16.6% | 19,073 | +15.8% | 0.00% | 0.0% |
| Q3 2017 | $956,000 | -68.2% | 16,470 | -33.7% | 0.00% | -66.7% |
| Q2 2017 | $3,006,000 | +6.4% | 24,832 | -0.6% | 0.00% | 0.0% |
| Q1 2017 | $2,824,000 | +145.8% | 24,977 | +119.7% | 0.00% | +200.0% |
| Q4 2016 | $1,149,000 | -39.0% | 11,371 | -0.7% | 0.00% | -50.0% |
| Q3 2016 | $1,884,000 | +15.5% | 11,446 | +0.1% | 0.00% | 0.0% |
| Q2 2016 | $1,631,000 | +2664.4% | 11,434 | +2374.9% | 0.00% | – |
| Q1 2016 | $59,000 | -28.9% | 462 | -16.8% | 0.00% | – |
| Q4 2015 | $83,000 | -37.1% | 555 | -30.1% | 0.00% | – |
| Q3 2015 | $132,000 | -85.5% | 794 | -78.9% | 0.00% | -100.0% |
| Q2 2015 | $909,000 | +91.0% | 3,766 | +123.0% | 0.00% | 0.0% |
| Q1 2015 | $476,000 | +242.4% | 1,689 | +90.4% | 0.00% | – |
| Q4 2014 | $139,000 | +24.1% | 887 | +88.3% | 0.00% | – |
| Q3 2014 | $112,000 | -20.6% | 471 | -20.8% | 0.00% | – |
| Q2 2014 | $141,000 | -74.5% | 595 | -64.5% | 0.00% | -100.0% |
| Q1 2014 | $553,000 | – | 1,675 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |